JP2017514813A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514813A5 JP2017514813A5 JP2016563822A JP2016563822A JP2017514813A5 JP 2017514813 A5 JP2017514813 A5 JP 2017514813A5 JP 2016563822 A JP2016563822 A JP 2016563822A JP 2016563822 A JP2016563822 A JP 2016563822A JP 2017514813 A5 JP2017514813 A5 JP 2017514813A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- compound
- lncrna
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091046869 Telomeric non-coding RNA Proteins 0.000 claims description 32
- 230000014509 gene expression Effects 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 23
- 150000007523 nucleic acids Chemical group 0.000 claims description 16
- 108020005198 Long Noncoding RNA Proteins 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 12
- 208000006029 Cardiomegaly Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 238000011529 RT qPCR Methods 0.000 claims description 2
- 108091023040 Transcription factor Proteins 0.000 claims description 2
- 102000040945 Transcription factor Human genes 0.000 claims description 2
- 206010047295 Ventricular hypertrophy Diseases 0.000 claims description 2
- -1 antibody Proteins 0.000 claims description 2
- 230000003828 downregulation Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 210000005003 heart tissue Anatomy 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 238000004020 luminiscence type Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 238000011002 quantification Methods 0.000 claims description 2
- 238000003753 real-time PCR Methods 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 238000011895 specific detection Methods 0.000 claims description 2
- 230000003827 upregulation Effects 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14165504.3 | 2014-04-22 | ||
| EP14165504 | 2014-04-22 | ||
| PCT/EP2015/058684 WO2015162161A1 (en) | 2014-04-22 | 2015-04-22 | Lncrnas for therapy and diagnosis of cardiac hypertrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019152429A Division JP6805304B2 (ja) | 2014-04-22 | 2019-08-23 | 心肥大の治療および診断のためのｌｎｃＲＮＡ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514813A JP2017514813A (ja) | 2017-06-08 |
| JP2017514813A5 true JP2017514813A5 (enExample) | 2018-03-29 |
| JP6577960B2 JP6577960B2 (ja) | 2019-09-18 |
Family
ID=50630577
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563822A Active JP6577960B2 (ja) | 2014-04-22 | 2015-04-22 | 心肥大の治療および診断のためのｌｎｃＲＮＡ |
| JP2019152429A Active JP6805304B2 (ja) | 2014-04-22 | 2019-08-23 | 心肥大の治療および診断のためのｌｎｃＲＮＡ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019152429A Active JP6805304B2 (ja) | 2014-04-22 | 2019-08-23 | 心肥大の治療および診断のためのｌｎｃＲＮＡ |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20170183652A1 (enExample) |
| EP (2) | EP3467111B1 (enExample) |
| JP (2) | JP6577960B2 (enExample) |
| CN (2) | CN117224687A (enExample) |
| CA (1) | CA2945559A1 (enExample) |
| DK (2) | DK3467111T3 (enExample) |
| ES (2) | ES2706878T3 (enExample) |
| HU (2) | HUE041700T2 (enExample) |
| PL (2) | PL3467111T3 (enExample) |
| TR (1) | TR201818825T4 (enExample) |
| WO (1) | WO2015162161A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201608907D0 (en) * | 2016-05-20 | 2016-07-06 | Ucl Business Plc | Means for modulating gene expression |
| US11667974B2 (en) | 2017-06-12 | 2023-06-06 | Firalis Sa | Diagnostic, prognostic and therapeutic uses of long noncoding RNAs for pathologies and toxicities inducing heart disorders |
| CN111032093A (zh) * | 2017-06-19 | 2020-04-17 | 洛桑大学 | 控制心肌纤维化和重塑的方法和组合物 |
| CN107326072A (zh) * | 2017-06-23 | 2017-11-07 | 陈梦麟 | Linc00702及其在调控心血管系统中的应用 |
| WO2019014656A1 (en) | 2017-07-14 | 2019-01-17 | Han Si Ping | METALLIC OLIGONUCLEOTIDE JONCTIONS FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS |
| EP3665281A4 (en) * | 2017-08-10 | 2021-05-05 | City of Hope | CONDITIONAL SIRNA AND ITS USE IN THE TREATMENT OF CARDIAC HYERTROPHY |
| JP7566741B2 (ja) | 2018-08-10 | 2024-10-15 | シティ・オブ・ホープ | プログラム可能なｓｉＲＮＡ及びその使用 |
| SG11202110607WA (en) | 2019-04-01 | 2021-10-28 | Tenaya Therapeutics Inc | Adeno-associated virus with engineered capsid |
| CN110229879B (zh) * | 2019-07-01 | 2022-11-18 | 青岛大学 | 一种piRNA-500核苷酸类似物及其反义核苷酸的应用和应用其的产品 |
| CN110878348B (zh) * | 2019-11-19 | 2023-03-28 | 南京启医科技有限公司 | 一种具有较高特异性的心衰lnc RNA生物标志物及其检测方法和应用 |
| CN111690673A (zh) * | 2020-06-22 | 2020-09-22 | 扬州大学 | 一种lncRNA通过编码小肽促进PGCs形成的验证方法 |
| CN112494651A (zh) * | 2020-09-30 | 2021-03-16 | 吉林大学 | lncRNA H19作为分子靶点在动脉粥样硬化治疗中的应用 |
| MX2023003984A (es) * | 2020-10-09 | 2023-04-24 | Tenaya Therapeutics Inc | Metodos y composiciones para terapia genica con placofilina-2. |
| US11781156B2 (en) | 2020-10-09 | 2023-10-10 | Tenaya Therapeutics, Inc. | Plakophillin-2 gene therapy methods and compositions |
| CN114959008B (zh) * | 2022-04-20 | 2024-11-26 | 华中科技大学同济医学院附属协和医院 | 长链非编码RNA-lnc-TSI的用途 |
| CN116179545B (zh) * | 2022-09-09 | 2025-10-31 | 上海工程技术大学 | LncRNA Gm20257在制备防治病理性心肌肥厚药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
| US6451594B1 (en) | 1998-09-11 | 2002-09-17 | The Regents Of The University Of California | Recombinant adenovirus for tissue specific expression in heart |
| GB0112343D0 (en) | 2001-05-21 | 2001-07-11 | Norske Stats Oljeselskap | Well treatment |
| AU2003291631A1 (en) * | 2002-10-03 | 2004-04-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method for regulating expression genes |
| WO2008104290A1 (en) * | 2007-02-27 | 2008-09-04 | Bayer Schering Pharma Aktiengesellschaft | H19 as a biomarker for ppara modulators |
| US8383346B2 (en) | 2008-06-13 | 2013-02-26 | Codexis, Inc. | Combined automated parallel synthesis of polynucleotide variants |
-
2015
- 2015-04-22 CN CN202310780826.3A patent/CN117224687A/zh active Pending
- 2015-04-22 EP EP18201238.5A patent/EP3467111B1/en active Active
- 2015-04-22 JP JP2016563822A patent/JP6577960B2/ja active Active
- 2015-04-22 HU HUE15717502A patent/HUE041700T2/hu unknown
- 2015-04-22 CN CN201580033597.2A patent/CN106488777A/zh active Pending
- 2015-04-22 EP EP15717502.7A patent/EP3134526B1/en active Active
- 2015-04-22 WO PCT/EP2015/058684 patent/WO2015162161A1/en not_active Ceased
- 2015-04-22 DK DK18201238.5T patent/DK3467111T3/da active
- 2015-04-22 TR TR2018/18825T patent/TR201818825T4/tr unknown
- 2015-04-22 DK DK15717502.7T patent/DK3134526T3/en active
- 2015-04-22 ES ES15717502T patent/ES2706878T3/es active Active
- 2015-04-22 CA CA2945559A patent/CA2945559A1/en active Pending
- 2015-04-22 HU HUE18201238A patent/HUE057484T2/hu unknown
- 2015-04-22 ES ES18201238T patent/ES2906995T3/es active Active
- 2015-04-22 PL PL18201238T patent/PL3467111T3/pl unknown
- 2015-04-22 PL PL15717502T patent/PL3134526T3/pl unknown
- 2015-04-22 US US15/305,976 patent/US20170183652A1/en not_active Abandoned
-
2018
- 2018-06-25 US US16/017,375 patent/US11371043B2/en active Active
-
2019
- 2019-08-23 JP JP2019152429A patent/JP6805304B2/ja active Active
-
2022
- 2022-04-12 US US17/658,957 patent/US20220315924A1/en active Pending
- 2022-07-12 US US17/811,995 patent/US20220348920A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514813A5 (enExample) | ||
| Schmitz et al. | Longer work/rest intervals during high-intensity interval training (HIIT) lead to elevated levels of miR-222 and miR-29c | |
| US20220315924A1 (en) | Lncrnas for therapy and diagnosis of cardiac hypertrophy | |
| Matsuura et al. | Circulating let‐7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C | |
| Roncarati et al. | Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy | |
| Cheng et al. | A translational study of urine miRNAs in acute myocardial infarction | |
| Wei et al. | What do we know about the cardiac benefits of exercise? | |
| US8574838B2 (en) | Methods and kits for miRNA isolation and quantitation | |
| Kakimoto et al. | MicroRNA deep sequencing reveals chamber-specific miR-208 family expression patterns in the human heart | |
| Soeki et al. | Relationship between local production of microRNA-328 and atrial substrate remodeling in atrial fibrillation | |
| JP6755242B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| Meloche et al. | miRNAs in PAH: biomarker, therapeutic target or both? | |
| JP2018518147A5 (enExample) | ||
| Kitow et al. | Mitochondrial long noncoding RNAs as blood based biomarkers for cardiac remodeling in patients with hypertrophic cardiomyopathy | |
| JP2013503617A5 (enExample) | ||
| Muthiah et al. | Longitudinal structural, functional, and cellular myocardial alterations with chronic centrifugal continuous-flow left ventricular assist device support | |
| Janssen et al. | Cardiac expression of deiodinase type 3 (Dio3) following myocardial infarction is associated with the induction of a pluripotency microRNA signature from the Dlk1-Dio3 genomic region | |
| JP2015521475A5 (enExample) | ||
| Bei et al. | MicroRNAs mediate beneficial effects of exercise in heart | |
| Kmecova et al. | Disease severity–related alterations of cardiac microRNAs in experimental pulmonary hypertension | |
| JP2019518439A5 (enExample) | ||
| WO2013179672A1 (ja) | 子宮内膜症の判定方法 | |
| Hulanicka et al. | The transcriptomic profile of peripheral blood nuclear cells in dogs with heart failure | |
| KR20150131555A (ko) | 근육노화 진단 및 치료를 위한 마이크로rna-136 | |
| Zhao et al. | Leveraging extracellular non-coding RNAs to diagnose and treat heart diseases |